»ÔÈðÍÑÏú×¢Éä¼Á£¬¹úÒ©¼¯ÍÅÊ×¼Ò¹ýÆÀØ¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ

Ò½ÏßÒ©ÎÅ
1¡¢12ÔÂ23ÈÕ£¬¹úÒ©¼¯ÍÅÉϺ£ÏÖ´úÖÆÒ©Ðû²¼Í¨¸æ³Æ£¬¿Ø¹É×Ó¹«Ë¾¹úÒ©Ò»ÐÄÖÆÒ©µÄ×¢ÉäÓð¢ÌǰûÜÕ»ñÅúÉÏÊУ¬¶øÖÊÁÏÒ©°¢ÌǰûÜÕҲͬʱͨ¹ý¹ØÁªÉóÆÀ¡£×¢ÉäÓð¢ÌǰûÜÕÊÇ»ÔÈðµÄÍÑÏú¿¹Ö×ÁöÒ©Î¹úÒ©Ò»ÐÄÖÆÒ©°´Ð·ÖÀàÉ걨ÉÏÊУ¬»ñÅúºóÄÃÏÂÊ×¼Ò¹ýÆÀ¡£
2¡¢12ÔÂ23ÈÕ£¬Öйú¹ú¼ÒÒ©¼à¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©¹ÙÍø¹«Ê¾£¬°²½ø£¨Amgen£©É걨ÁË1ÀàÐÂÒ©AMG 451µÄÁÙ´²ÊÔÑéÉêÇ룬²¢»ñµÃÊÜÀí¡£¹ûÕæ×ÊÁÏÏÔʾ£¬AMG 451ÊÇÒ»ÖÖDZÔÚ¡°first-in-class¡±È«ÈËÔ´»¯¿¹OX40µ¥¿Ë¡¿¹Ì壬°²½øÕýÔÚ¿ªÕ¹¸ÃÒ©ÖÎÁÆÌØÓ¦ÐÔÆ¤Ñ×µÄ3ÆÚÁÙ´²Ñо¿¡£
3¡¢12ÔÂ22ÈÕ£¬ÔóÄÉÊËÉúÎïÔÚClinicaltrials.govÉÏ×¢²áÁËObexelimabµÄÈýÆÚÁÙ´²£¬ÓÃÓÚÖÎÁÆIgG4Ïà¹Ø¼²²¡¡£ObexelimabΪһ¿î¾ÓÉ¿¹Ì幤³ÌˢеÄCD19¿¹Ì壬ΪÔóÄÉÊËÉúÎïµÄÊ×·¢¹ÜÏߣ¬±ðµÄÉÐÓÐTNF¦Á¿¹Ìå¡¢CTLA4-IgÈÚºÏÂѰס¢IGF-1R¿¹ÌåµÈÔÚÑÐÒ©Îï¡£
4¡¢12ÔÂ22ÈÕ£¬NMPA¹ÙÍøÐû²¼×îÐÂÒ»ÅúÒ©Æ·»ñÅúÐÅÏ¢£¬³É¶¼¿µºëÒ©Òµ¼¯ÍŵIJÝËᰬ˾Î÷̪ÆÕÀ¼¿Ú·þÈÜÒº»ñÅúÉÏÊС£ÏÖÔÚº£ÄÚÊг¡ÉÏÏúÊ۵ݬ˾Î÷̪ÆÕÀ¼Ö»ÓÐͨËׯ¬¼Á£¬¿µºëÒ©ÒµÊǿڷþÈÜÒºÊ×¼Ò»ñÅúÆóÒµ¡£
ͶÈÚÒ©ÊÂ
1¡¢12ÔÂ23ÈÕ£¬ºÍ²¬Ò½Ò©Ðû²¼Í¨¸æ£¬ÆäÓë¿ÆÂײ©Ì©ÏàÖú¿ª·¢µÄ2¿îADCÊÚȨ¸øµÚÈý·½£¬Æ¾Ö¤ÐÒ飬ºÍ²¬Ò½Ò©×Ó¹«Ë¾ÅµÄÉÉúÎï»ñµÃÔ¤¸¶¿î¡¢Àï³Ì±®½ð¶î¼°ÏúÊ۷ֳɵÄ30%£¬ÆäÖеÚ1¿î²úÆ·µÄÔ¤¸¶¿îΪ3000ÍòÃÀÔª£¬ºÍ²¬Ò½Ò©×Ó¹«Ë¾ÅµÄÉÉúÎïËùµÃΪ900ÍòÃÀÔª¡£
2¡¢12ÔÂ22ÈÕ£¬¿ÆÂ×Ò©Òµ½«7¿îÔÚÑÐÁÙ´²Ç°½×¶ÎµÄADCÐÂÒ©ÊÚȨ¸øÄ¬É³¶«£¬ºóÕßÖ®¸»ºñ1.75ÒÚÃÀÔªÔ¤¸¶¿îÒÔ¼°93ÒÚÃÀÔªÀï³Ì±®½ð¶î¡£
¿Æ¼¼Ò©ÑÐ
1¡¢¿ËÈÕ£¬À´×ÔÎ人´óѧÈËÃñÒ½ÔºµÄÑо¿ÕßÃÇÔÚMolecular Therapy: Nucleic AcidsÔÓÖ¾ÉϽÒÏþÁ˵ÄÑо¿Õ¹ÏÖÁËCTSBͨ¹ýµ÷ÀíÐļ¡Ï¸°û½¹Íö£¬¼ÓÖØDCMÒýÆðµÄÐÄÔàÖØ¹¹£¬¼ÓÖØÐĹ¦Ð§²»È«¡£Í¨¹ýÓëNLRP3Ï໥×÷Óã¬CTSBµ÷ÀíÑ×֢СÌåµÄÐγɣ¬²¢Òý·¢NLRP3½éµ¼µÄ½¹ÍöºÍÑ×Ö¢¡£Òò´Ë£¬CTSB¿ÉÄܳÉΪÖÎÁÆÀ©ÕÅÐÍÐ¡ÐµÄÖÎÁÆÒªÁìµÄ°Ðµã[1]¡£
[1] Chen Liu et al. Cathepsin B deteriorates diabetic cardiomyopathy induced by streptozotocin via promoting NLRP3-mediated pyroptosis. Mol Ther Nucleic Acids. 2022 Sep 23;30:198-207. doi: 10.1016/j.omtn.2022.09.019
